Recent Finacing
Recent Raise
Somagenetix is a University of Zurich spin-off developing a lentiviral platform for one-time gene therapies targeting phagocyte disorders, with lead candidate SGX-001 for p47‑CGD heading toward clinical application.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Somagenetix.
